Open Access Article

What Kind of Rash Is It?: Deciphering the Dermatologic Toxicities of Biologic and Targeted Therapies

Peg Esper

Danielle Gale

Paula M. Muehlbauer

toxins, biotherapy/targeted therapy
CJON 2007, 11(5), 659-666. DOI: 10.1188/07.CJON.659-666

An overwhelming number of new agents, including targeted agents with unique mechanisms of action, are available in oncology practice today. Along with the benefit of new treatments for patients comes the unfamiliarity of associated toxicities and learning the best methods to minimize side effects. One such toxicity has been the spectrum of dermatologic reactions from some of the newer small-molecule inhibitors and monoclonal antibodies. Scientific evidence describing the unique rashes and methodologies to treat various cutaneous toxicities with specific agents is extremely limited. This article reviews the currently available literature related to dermatologic toxicities observed with many newer targeted therapies. Current recommendations for management are based on practices implemented during clinical trials and postmarketing practices. Additional research is needed to further elucidate the most efficacious methods for treating side effects observed with newer targeted therapies.

Jump to a section


    Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J.M., Herbst, R., et al. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. Journal of Clinical Oncology, 20, 110-124.
    Azagury, M., Pauwels, C., Kornfeld, S., Bataille, N., & Perie, G. (1996). Severe cutaneous reactions following interferon injections. European Journal of Cancer, 32, 1821.
    Bauer, C. (2005, Fall). Skin toxicities of EGFR inhibitors. Oncology Nursing Society Metro Detroit Chapter Capsule, 20, 1-4.
    Busam, K.J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A.C. (2001). Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology, 144, 1169-1176.
    Cnudde, F., Gharakhanian, S., Luboinski, J., Dry, J., & Rozenbaum, W. (1991). Cutaneous local necrosis following interferon injections. International Journal of Dermatology, 30, 147.
    Cohen, M.H., Johnson, J.R., & Pazdur, R. (2005). U.S. Food and Drug Administration drug approval summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clinical Cancer Research, 11, 12-19.
    Cuaron, L., & Thompson, J. (2001). The interferons. In P.T. Rieger (Ed.), Biotherapy: A comprehensive overview (2nd ed., pp. 125-191). Sudbury, MA: Jones and Bartlett.
    Dick, S.E., & Crawford, G.H. (2005). Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Community Oncology, 2, 492-496.
    Gale, D.M. (2005). Nursing implications of biotherapy and molecular targeted therapy. In J.K. Itano & K.N. Taoka (Eds.), Core curriculum for oncology nursing (4th ed., pp. 763-785). St. Louis, MO: Elsevier Saunders.
    Gallelli, L., Guadagnino, V., Caroleo, B., Marigliano, N., & De Sarro, D. (2004). Cutaneous ulceration induced by interferon alfa. Annals of Pharmacotherapy, 38, 173-174.
    Harari, P.M. (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer, 11, 689-708.
    Harding, J., & Burtness, B. (2005). Cetuximab: An epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs of Today, 41(2), 107-127.
    Herbst, R.S., LoRusso, P.M., Purdom, M., & Ward, D. (2003). Dermatologic side effects associated with gefitinib therapy: Clinical experience and management. Clinical Lung Cancer, 4, 366-369.
    Huang, S.M., & Harari, P.M. (1999). Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results. Investigational New Drugs, 17, 259-269.
    King, L.E., Jr., Gates, R.E., Stoscheck, C.M., Underwood, R.A., & Nanney, L.B. (1990). Epidermal growth factor/transforming growth factor alpha receptors and psoriasis. Journal of Investigative Dermatology, 95(Suppl. 5), 10S-12S.
    Lacouture, M.E. (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews: Cancer, 6, 803-812.
    Laux, I., Jain, A., Singh, S., & Agus, D.B. (2006). Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. British Journal of Cancer, 94, 85-92.
    Lenz, H.J. (2006). Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events. Oncology, 20(5, Suppl. 2), 5-13.
    Mavroukakis, S.A., Muehlbauer, P.M., White, R.L., & Schwartzentruber, D.J. (2001). Clinical pathways for managing patients receiving interleukin 2. Clinical Journal of Oncology Nursing, 5, 207-217.
    National Cancer Institute. (2006). Common terminology criteria for adverse events. Retrieved September 5, 2007, from
    Perez-Soler, R., Delord, J.P., Halpern, A., Kelly, K., Krueger, J., Sureda, B.M., et al. (2005). HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist, 10, 345-356.
    Perez-Soler, R., & Saltz, L. (2005). Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? Journal of Clinical Oncology, 23, 5235-5246.
    Reynolds, N. (2004). Cetuximab: In the treatment of metastatic colorectal cancer. Drugs, 64, 109.
    Rhee, J., Oishi, K., Garey, J., & Kim, E. (2005). Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clinical Colorectal Cancer, 5(Suppl. 2), S101-S106.
    Robert, C., Soria, J.C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., et al. (2005). Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncology, 6, 491-500.
    Roskoski, R., Jr. (2004). The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and Biophysical Research Communications, 319, 1-11.
    Rowinsky, E.K. (2004). The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annual Review of Medicine, 55, 433-457.
    Schwartzentruber, D.J. (2000). Interleukin-2: Clinical applications: Principles of administration and management of side effects. In S.A. Rosenberg (Ed.), Principles and practice of the biologic therapy of cancer (3rd ed., pp. 32-50). Philadelphia: Lippincott Williams and Wilkins.
    Shah, N.T., Kris, M.G., Pao, W., Tyson, L.B., Pizzo, B.M., Heinemann, M.H., et al. (2005). Practical management of patients with nonsmall cell lung cancer treated with gefitinib. Journal of Clinical Oncology, 23, 165-174.
    Stafford-Fox, V., & Guindon, K.M. (2000). Cutaneous reactions associated with alpha interferon therapy. Clinical Journal of Oncology Nursing, 4, 164-168.
    Warner, G.T., & Plosker, G.L. (2002). Clindamycin/benzoyl peroxide gel: A review of its use in the management of acne. American Journal of Clinical Dermatology, 3, 349-360.